Drug intelligence / Profile preview

PAS-002 (Porton Advanced)

Development stage: Unknown
Lead developer: Porton Advanced Solutions
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

PAS-002 is a chimeric antigen receptor T-cell (CAR-T) therapy being developed by Porton Advanced for the treatment of solid tumors, specifically pancreatic and gastric cancers. The therapy is engineered to simultaneously target two tumor-associated antigens: Natural Killer Group 2 Member D Ligands (NKG2DL) and Claudin 18.2 (CLDN18.2). By recognizing these targets on the surface of tumor cells, the CAR-T cells mediate direct T-cell cytotoxicity. PAS-002 is currently in Phase 1 development, involving investigator-initiated clinical trials and pre-IND stages in China.

Beyond the preview

Go deeper on PAS-002 (Porton Advanced).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PAS-002 (Porton Advanced).

Explore the full profile